Adelene Perkins - Infinity Pharmaceuticals Insider

Infinity Pharmaceuticals Inc -- USA Stock  

USD 2.7  0.25  8.47%

Chairman of The Board, CEO and Pres

Ms. Adelene Q. Perkins serves as Chairman of the Board, Chief Executive Officer of the Company. She was Chairman of the Board, President, Chief Executive Officer of Infinity Pharmaceuticals Inc. She has served as our President and Chief Executive Officer since January 2010, President and Chief Business Officer from October 2008 through December 2009 and as our Executive Vice President and Chief Business Officer between September 2006 and October 2008. Ms. Perkins served as Executive Vice President of IPI from February 2006 until its merger with DPI in September 2006 and Chief Business Officer of IPI from June 2002 until the DPI merger. Prior to joining IPI, Ms. Perkins served as Vice President of Business and Corporationrationrate Development of TransForm Pharmaceuticals, Inc., a private pharmaceutical company, from 2000 to 2002. From 1992 to 1999, Ms. Perkins held various positions at Genetics Institute, most recently serving as Vice President of Emerging Business and General Manager of the DiscoverEase business unit. Ms. Perkins has served as a director of the Biotechnology Industry Organization since 2012, a director of Project Hope, a notforprofit social services company since 2013, a director of the Massachusetts Life Sciences Center, a quasipublic agency of the Commonwealth of Massachusetts, since 2014, a director of the Massachusetts Biotechnology Council, a notforprofit organization, since 2014, and a director of Padlock Therapeutics, a privately held biopharmaceutical company since 2015. From 1985 to 1992, Ms. Perkins held a variety of positions at Bain Company, a strategy consulting firm
Age: 56  Chairman Since 2017  MBA    
617-453-1000  www.infi.com
Perkins received a B.S. in Chemical Engineering from Villanova University and an M.B.A. from Harvard Business School.

Management Efficiency

The company has return on total asset (ROA) of (26.58) % which means that it has lost $26.58 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (78.61) % meaning that it created substantial loss on money invested by shareholders.

Similar Executives

Entity Summary

Infinity Pharmaceuticals, Inc., a drug discovery and development company, discovers, develops, and delivers medicines to patients with difficulttotreat diseases. Infinity Pharmaceuticals Inc (INFI) is traded on NASDAQ in USA. It is located in MASSACHUSETTS, U.S.A and employs 48 people. Infinity Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.

Did you try this?

Run Idea Optimizer Now
   

Idea Optimizer

Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Hide  View All  Next  Launch Idea Optimizer
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Infinity Pharmaceuticals Inc to your portfolio

Top Management

Infinity Pharmaceuticals Leadership Team
Joseph Pearlberg, President, Ph.D
Melissa Hackel, President, MBA
William Bertrand, President
Vito Palombella, EVP
Jeffrey Berkowitz, Director
Lawrence Bloch, President, MBA
Norman Selby, Director, MBA
Jose Baselga, Director, Ph.D
Michael Venuti, Director, Ph.D
Franklin Moss, Executive
David Roth, Executive
Michael Kauffman, Director
Jaren Madden, Director
Eric Lander, Director, Ph.D
Julian Adams, President
Anthony Evnin, Director, Ph.D
Winston Lam, President, MBA
Gwendolyn Fyfe, Director
Sujay Kango, President, MBA
Ian Smith, Director
Adelene Perkins, Chairman, MBA

Stock Performance

Infinity Pharmaceuticals Performance Indicators